Skip to main content

Ileus

10
Pipeline Programs
7
Companies
10
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
3
0
7
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

7 companies ranked by most advanced pipeline stage

ViiV Healthcare
ViiV HealthcareNC - Durham
5 programs
4
AlvimopanPhase 3
AlvimopanPhase 3
AlvimopanPhase 3
alvimopanPhase 3
AlvimopanN/A
Palisade Bio
Palisade BioCARLSBAD, CA
2 programs
1
1
LB1148Phase 3
LB1148Phase 2
Biocorp
BiocorpFrance - Issoire
2 programs
1
1
LB1148Phase 31 trial
LB1148Phase 21 trial
Active Trials
NCT02836470Completed112Est. Sep 2023
NCT05470387Terminated23Est. Aug 2023
Bausch Health
Bausch HealthQUEBEC, Quebec, Canada
1 program
1
MOA-728Phase 31 trial
Active Trials
NCT00528970Completed374Est. Feb 2008
Helsinn
HelsinnIreland - Dublin
1 program
1
IpamorelinPhase 21 trial
Active Trials
NCT00672074Completed117Est. Dec 2009
GSK
GSKLONDON, United Kingdom
5 programs
AlvimopanN/A1 trial
AlvimopanPHASE_31 trial
AlvimopanPHASE_31 trial
AlvimopanPHASE_31 trial
alvimopanPHASE_31 trial
Active Trials
NCT01150760Completed7,050Est. Aug 2010
NCT00388401Completed510Est. Jun 2003
NCT00388479Completed666Est. Nov 2003
+2 more trials
electroCore
electroCoreNJ - Rockaway
1 program
ElectroCore RMS-1100 Resolution Motility System™N/A1 trial
Active Trials
NCT00854074Withdrawn0Est. Jan 2010

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
BiocorpLB1148
Bausch HealthMOA-728
GSKalvimopan
GSKAlvimopan
GSKAlvimopan
GSKAlvimopan
BiocorpLB1148
HelsinnIpamorelin
GSKAlvimopan
electroCoreElectroCore RMS-1100 Resolution Motility System™

Clinical Trials (10)

Total enrollment: 9,963 patients across 10 trials

NCT05470387BiocorpLB1148

A Study to Evaluate LB1148 for Return of Bowel Function in Subjects Undergoing Bowel Resection

Start: Jun 2022Est. completion: Aug 202323 patients
Phase 3Terminated
NCT00528970Bausch HealthMOA-728

A Study Evaluating Intravenous (IV) MOA-728 for the Treatment of Postoperative Ileus (POI) in Participants After Ventral Hernia Repair

Start: Oct 2007Est. completion: Feb 2008374 patients
Phase 3Completed
NCT00205842GSKalvimopan

Study of Alvimopan for the Management of Opioid-induced Postoperative Bowel Dysfunction/Postoperative Ileus

Start: Jun 2004Est. completion: Dec 2005660 patients
Phase 3Completed
NCT00388401GSKAlvimopan

Study of Alvimopan for the Management of Opioid-induced Postoperative Bowel Dysfunction/Postoperative Ileus

Start: Jan 2002Est. completion: Jun 2003510 patients
Phase 3Completed
NCT00388479GSKAlvimopan

Study of Alvimopan for the Management of Opioid-induced Postoperative Bowel Dysfunction/ Postoperative Ileus

Start: Dec 2001Est. completion: Nov 2003666 patients
Phase 3Completed
NCT00388258GSKAlvimopan

Study of Alvimopan for the Management of Opioid-induced Postoperative Bowel Dysfunction/Postoperative Ileus

Start: Mar 2001Est. completion: Dec 2002451 patients
Phase 3Completed
NCT02836470BiocorpLB1148

A Study to Evaluate LB1148 for Return of Gastrointestinal Function and Adhesions in Subjects Undergoing Bowel Resection

Start: Oct 2019Est. completion: Sep 2023112 patients
Phase 2Completed
NCT00672074HelsinnIpamorelin

Safety and Efficacy of Ipamorelin for Management of Post-Operative Ileus

Start: Apr 2008Est. completion: Dec 2009117 patients
Phase 2Completed
NCT01150760GSKAlvimopan

Clinical Outcomes After Bowel Resection in Patients Receiving Alvimopan Versus Patients Not Receiving Alvimopan in the Premier Perspective Database

Start: Apr 2010Est. completion: Aug 20107,050 patients
N/ACompleted
NCT00854074electroCoreElectroCore RMS-1100 Resolution Motility System™

Neurostimulation for the Treatment of Post-Operative Ileus

Start: Jul 2009Est. completion: Jan 20100
N/AWithdrawn

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

7 late-stage (Phase 3) programs, potential near-term approvals
7 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.